Pharma BD Deal Intelligence
Amgen acquired Otezla (apremilast) for $13.4B from Celgene psoriasis drug divestiture.
Amgen Q3 2025 results: recorded a $400M Otezla intangible-asset impairment charge, reflecting Otezla performance below the long-term acquisition plan.
Amgen Q4/FY2025 results: Otezla full-year sales $2,265M, up 7% YoY (FY2024 $2,126M), driven by volume growth and favorable sales deductions.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Amgen acquired Otezla (apremilast) for $13.4B from Celgene psoriasis drug divestiture.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Otezla (from Celgene/BMS) (this deal) | 2019 | $13.4B | 68 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / BeiGene Ltd. | 2020 | $2.8B | 68 |
← Browse all deals · How we score deals
More: 2019 deals · Amgen Inc. deals · Dermatology deals